UTI
UTI
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
35 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
UTI has an insider buy conviction of 50%, compared to the Unknown sector buy average of 50%. UTI ranks #59 in insider activity out of 261 tracked companies in its industry.
Multiple Insiders
P - Purchase Insiders
$0 total
Over the last 90 days, corporate insiders at UTI (UTI) engaged in a total of 35 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for UTI shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 152.3K shares valued at $0 on Sep 21, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering UTI and the Unknown sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
The Spinoff Separation: Tracking Post-Spinoff Executive Ownership Trends
An investigation of corporate spinoffs, showing how executive equity allocations and post-separation insider transactions signal parent and subsidiary performance trajectories.
The Lockup Expiration Wave: Venture Capital Post-IPO Exit Strategies
A data-driven analysis of how venture capital firms and pre-IPO insiders manage lockup expirations, detailing block trade execution, distribution methods, and stock price impact.
a16z Capital Distributions vs. Open-Market Insider Buying: A 2026 Study
A 2026 empirical study comparing Andreessen Horowitz's in-kind share distributions to LPs against open-market insider purchases, revealing which signal better predicts 12-month price performance.
Institutional Ownership vs. Insider Trading: Understanding the Data Flow
High institutional ownership reduces information asymmetry, but does it also reduce the predictive power of insider trades? This analysis tests whether stocks with more than 70% institutional ownership show weaker Form 4 signal performance.
FAQs About UTI Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for UTI.